Edition:
United Kingdom

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.09USD
3:59pm GMT
Change (% chg)

$-0.08 (-6.84%)
Prev Close
$1.17
Open
$1.19
Day's High
$1.20
Day's Low
$1.09
Volume
85,759
Avg. Vol
164,417
52-wk High
$3.91
52-wk Low
$0.69

Latest Key Developments (Source: Significant Developments)

Vistagen Therapeutics posts Q2 loss of $0.53 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Vistagen Therapeutics Inc :Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update.Qtrly ‍basic and diluted net loss attributable to common stockholders per common share​ of $0.53.  Full Article

VistaGen Therapeutics files for offering of up to $23 mln of common stock
Wednesday, 18 Oct 2017 

Oct 19 (Reuters) - VistaGen Therapeutics Inc :VistaGen Therapeutics Inc files for offering of up to $23 million of common stock – SEC filing‍​.  Full Article

VistaGen Therapeutics reports Q3 loss per share $0.34
Monday, 13 Feb 2017 

VistaGen Therapeutics Inc : VistaGen Therapeutics reports fiscal third quarter 2017 financial results and provides corporate update .Q3 loss per share $0.34.  Full Article

Vistagen Therapeutics provides business outlook
Thursday, 22 Sep 2016 

Vistagen Therapeutics Inc : Vistagen Therapeutics provides business outlook and sets corporate milestones . Says Vistagen expects to report topline data from its NIMH-sponsored Phase 2a study in Q2 of 2017 . Expects to receive FDA fast track designation for AV-101 as adjunctive treatment for MDD during first half of 2017. .Company anticipates topline results for AV-101 from Phase 2b study to be reported in Q3 of 2018.  Full Article

Sphera Funds Management reports 7.6 pct passive stake in Vistagen Therapeutics as of May 11, 2016
Wednesday, 22 Jun 2016 

Vistagen Therapeutics Inc : Sphera Funds Management Ltd reports 7.6 percent passive stake in Vistagen Therapeutics Inc as of May 11, 2016 - Sec filing Source - http://1.usa.gov/28PKYsC (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Vistagen Therapeutics appoints Mark Smith as chief medical officer
Monday, 20 Jun 2016 

Vistagen Therapeutics Inc : Appoints Mark A. Smith, as chief medical officer . Expects to report topline data from phase 2A clinical study in Q2 of 2017 and is preparing to advance AV-101 into a phase 2B .Vistagen Therapeutics appoints pharmaceutical CNS drug development executive Mark A. Smith M.D., PH.D. as chief medical officer.  Full Article

Empery Asset Management reports 9.87 pct passive stake in Vistagen Therapeutics
Thursday, 19 May 2016 

Vistagen Therapeutics Inc :Empery Asset Management Lp reports 9.87 pct passive stake in Vistagen Therapeutics Inc, as of May 11, 2016 - SEC filing.  Full Article

Vistagen announces Nasdaq listing and pricing of $10.0 million public offering
Wednesday, 11 May 2016 

Vistagen Therapeutics Inc : Warrants will have an exercise price of $5.30 , are exercisable immediately, and will have a term of five years . Says co's common stock will begin trading on nasdaq capital market under symbol ''vtgn" on may 11 , 2016 . Says announced pricing of its public offering of 2.4 million shares of common stock and warrants . Stocks and warrants priced at a combined price to public of $4.25 for aggregate gross proceeds of approximately $10.0 million .Vistagen announces nasdaq listing and pricing of $10.0 million public offering.  Full Article

Vistagen announces Nasdaq listing and pricing of $10.0 million public offering
Wednesday, 11 May 2016 

Vistagen Therapeutics Inc : Warrants will have an exercise price of $5.30 , are exercisable immediately, and will have a term of five years . Says co's common stock will begin trading on nasdaq capital market under symbol ''vtgn" on may 11 , 2016 . Says announced pricing of its public offering of 2.4 million shares of common stock and warrants . Stocks and warrants priced at a combined price to public of $4.25 for aggregate gross proceeds of approximately $10.0 million .Vistagen announces nasdaq listing and pricing of $10.0 million public offering.  Full Article

BRIEF-Vistagen Announces Pricing Of Underwritten Offering Of Common Stock And Warrants To Purchase Common Stock

* VISTAGEN ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK